A5000496377- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Immune Cell Function and Interaction
- HIV Research and Treatment
- SARS-CoV-2 detection and testing
- Neuroinflammation and Neurodegeneration Mechanisms
- Animal Virus Infections Studies
- Vaccine Coverage and Hesitancy
- Blood groups and transfusion
- Infection Control and Ventilation
- Monoclonal and Polyclonal Antibodies Research
- COVID-19 and healthcare impacts
- COVID-19 epidemiological studies
- T-cell and B-cell Immunology
- Long-Term Effects of COVID-19
- Respiratory viral infections research
HKU-Pasteur Research Pole
2022-2024
University of Hong Kong
2020-2024
Chulalongkorn University
2019
King Chulalongkorn Memorial Hospital
2019
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel with high nucleotide identity to SARS-CoV and SARS-related coronaviruses that have been detected in horseshoe bats, has spread across the world had global effect on healthcare systems economies1,2. A suitable small animal model is needed support development of vaccines therapies. Here we report pathogenesis transmissibility SARS-CoV-2 golden (Syrian) hamsters (Mesocricetus auratus). Immunohistochemistry assay demonstrated...
Few trials have compared homologous and heterologous third doses of COVID-19 vaccination with inactivated vaccines mRNA vaccines. The aim this study was to assess immune responses, safety, efficacy against SARS-CoV-2 infection following or third-dose either one dose CoronaVac (Sinovac Biotech; vaccine) BNT162b2 (Fosun Pharma-BioNTech; vaccine).
Long COVID occurs in a small but important minority of patients following COVID-19, reducing quality life and contributing to healthcare burden. Although research into underlying mechanisms is evolving, immunity understudied. SARS-CoV-2-specific T cell responses are key importance for viral clearance COVID-19 recovery. However, long COVID, the establishment persistence cells far from clear, especially beyond 12 mo postinfection postvaccination. We defined ex vivo antigen-specific B their...
Whole virion inactivated vaccine CoronaVac (C) and Spike (S) mRNA BNT162b2 (B) vaccines differ greatly in their ability to elicit neutralizing antibodies but have somewhat comparable effectiveness protecting from severe COVID-19. We conducted further analyses for a randomized trial (Cobovax study, NCT05057169) of third dose homologous heterologous booster vaccination, i.e. four interventions CC-C, CC-B, BB-C BB-B. Here, we assess immunogenicity beyond function, including S non-S with Fc...
ABSTRACT Background There are few trials comparing homologous and heterologous third doses of COVID-19 vaccination with inactivated vaccines mRNA vaccines. Methods We conducted an open-label randomized trial in adults >=18 years age who received two vaccine (CoronaVac) or (BNT162b2) >=6 months earlier, randomised 1:1 ratio to receive a dose either vaccine. compared the reactogenicity, immunogenicity cell-mediated immune responses, assessed efficacy against infections during follow-up....
Objectives: CD8+ T cells recognize human leukocyte antigen-peptide complex through the T-cell receptor. Although amino acid variation in receptor variable chains often affects antigen specificity, dimorphism beta chain constant region (TRBC1 and TRBC2) is not thought to affect function. A recent study suggested that adoptive transfer of TRBC1-specific chimeric antigen-receptor-T provided an option for leukemia therapy preserved immunity TRBC2 subset. This raises important question as whether...